PT-141 (Bremelanotide): How This Peptide Works for Sexual Dysfunction

PT-141 (Bremelanotide): How This Peptide Works for Sexual Dysfunction

Bremelanotide (PT-141, brand name Vyleesi) is a melanocortin receptor agonist peptide that the FDA approved in June 2019 as an on-demand injection for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It acts on melanocortin-4 receptors in the brain to raise desire and arousal rather than genital blood flow, and in the two RECONNECT phase 3 trials about 25% of women reported a meaningful increase in desire, compared with 17% on placebo (Kingsberg et al., 2019).

PT-141 is the only peptide-based treatment for sexual dysfunction that has earned FDA approval. Unlike Viagra, Cialis, and other PDE5 inhibitors that work on blood flow, PT-141 works through the central nervous system, activating melanocortin receptors in the brain that influence sexual arousal and desire. Clinicians also prescribe compounded PT-141 off label for men, and its benefit is specific to desire and arousal: no clinical trial has tested it for longevity or general wellness.

This distinction matters. Most sexual dysfunction treatments address the mechanical aspects of sexual function (erection quality, genital blood flow). PT-141 addresses the motivational component: the desire, arousal, and drive that precede the physical response. That makes it a different kind of tool, one that fills a gap blood-flow drugs leave open.

What Is PT-141 and Where Did It Come From?

PT-141’s origin story is one of medicine’s more interesting accidents. Researchers at the University of Arizona were studying Melanotan II, a synthetic peptide originally developed as a sunless tanning agent. Melanotan II activates melanocortin receptors, which stimulate melanin production in the skin (hence the tanning effect). During clinical trials, male participants reported an unexpected side effect: spontaneous erections.¹

This led researchers to investigate the sexual arousal effects more specifically. They modified Melanotan II to create PT-141 (bremelanotide), a cyclic peptide that retained the sexual arousal properties while reducing some of the other melanocortin effects. PT-141 specifically targets the melanocortin-4 receptor (MC4R), which is concentrated in brain areas involved in sexual arousal, motivation, and reward.²

After years of clinical development, the FDA approved bremelanotide in June 2019 under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. This made it the first (and currently only) on-demand treatment for low sexual desire.

Names you will see for the same drug

Bremelanotide is the generic name, PT-141 is the research code that peptide clinics still use, and Vyleesi is the FDA-approved autoinjector. Compounded versions are labeled PT-141 or bremelanotide acetate. Melanotan II is a different, older peptide that was never approved by the FDA, and it is not a substitute for prescribed bremelanotide.

How PT-141 Works: The Melanocortin Pathway

PT-141 differs from every other sexual dysfunction treatment because of where it acts: in the brain rather than in the blood vessels.

PDE5 inhibitors (sildenafil/Viagra, tadalafil/Cialis) work peripherally. They block the enzyme phosphodiesterase-5 in blood vessel walls, allowing nitric oxide to keep blood vessels dilated longer. The result is improved blood flow to the genitals. They do not affect desire, arousal, or motivation. They facilitate the mechanical response when the mental component is already present.³

PT-141 works centrally, in the brain. It activates melanocortin-4 receptors in the hypothalamus and limbic system, brain regions that process sexual arousal, desire, motivation, and reward. When MC4R is activated, it triggers downstream signaling through dopamine and oxytocin pathways that enhance:

• Sexual desire: the motivational drive to seek sexual activity
• Arousal: the physiological and psychological state of sexual readiness
• Genital response: increased genital sensitivity and blood flow (as a downstream effect of central arousal)

This central mechanism is why PT-141 can help patients for whom PDE5 inhibitors are insufficient. If the core issue is low desire rather than impaired blood flow, a blood-flow drug will not solve the problem. PT-141 addresses the upstream signal.

How long does PT-141 take to work?

Bremelanotide reaches its peak blood level about 1 hour after a subcutaneous injection, and its mean half-life is about 2.7 hours, according to the FDA prescribing information for Vyleesi. That is why the label asks for the dose at least 45 minutes before sexual activity. Clinicians commonly describe the window of effect as lasting several hours, and the label leaves the exact timing to the patient and prescriber based on response and side effects.

FDA Approval: What the Clinical Trials Showed

The FDA approval of Vyleesi was based on two phase III clinical trials (RECONNECT studies) enrolling approximately 1,247 premenopausal women with HSDD. HSDD is defined as persistently low sexual desire that causes personal distress, not explained by a medical condition, medication, or relationship issue.⁴

Both trials were identical, randomized, double-blind and placebo controlled, and each ran for 24 weeks, according to the FDA prescribing information. Women injected bremelanotide or placebo as needed before sexual activity, and the trials measured desire and distress on validated questionnaires.

Results from the RECONNECT trials:

• Approximately 25% of PT-141-treated women experienced a meaningful increase in sexual desire (compared to 17% on placebo)
• Approximately 35% of PT-141-treated women experienced a meaningful decrease in distress related to low desire (compared to 31% on placebo)
• The treatment effect was statistically significant but modest in absolute terms
• Responders reported the effects as genuinely meaningful to their quality of life

The numbers deserve honest context. The response rates are not dramatic. But for women who do respond, PT-141 filled a void that no other medication could address. Before Vyleesi, the only FDA-approved drug for female HSDD was flibanserin (Addyi), which requires daily dosing and carries alcohol restrictions. PT-141 works on demand, taken only when desired, which many patients and clinicians consider a significant advantage.⁵

What the approval does and does not cover

The FDA prescribing information for Vyleesi (2019) limits the indication to premenopausal women whose low desire is acquired, generalized and not caused by another condition, a relationship problem or a medication. It states that bremelanotide is not indicated for postmenopausal women, for men, or to enhance sexual performance. It also tells prescribers to stop treatment after 8 weeks if the patient reports no improvement.

Bremelanotide vs. Flibanserin (Addyi)

Bremelanotide and flibanserin are the two FDA-approved medicines for HSDD in premenopausal women, and they work in different ways. Flibanserin (Addyi), approved in 2015, is a daily oral tablet that acts on serotonin receptors. Bremelanotide is an as-needed injection that acts on melanocortin receptors. Women’s health clinicians, OB-GYNs and sexual medicine specialists usually choose between them based on dosing preference, alcohol use and side effects.

Neither drug is approved for men, and neither is a hormone. When low desire follows menopause or surgical removal of the ovaries, clinicians more often look at menopause care and hormone therapy first.

Off-Label Use in Men

While PT-141 is FDA-approved only for premenopausal women with HSDD, it is widely used off-label for male sexual dysfunction. The melanocortin receptor pathway is active in both sexes, and several studies have examined PT-141 in men.

Evidence in Male Erectile Dysfunction

Phase II trials of PT-141 in men with erectile dysfunction showed:

• Improved erectile function compared to placebo, measured by rigidity monitoring
• Effects that were independent of the PDE5 inhibitor pathway, meaning PT-141 worked even in some men who had not responded to Viagra or Cialis
• Particular benefit in men whose ED had a significant psychological or desire-related component
• The ability to produce erections without direct physical stimulation (unlike PDE5 inhibitors, which typically require sexual stimulation to work)

A pivotal study by Diamond et al. (2005) demonstrated that PT-141 produced erections in 67% of men with ED, including a subset of men who were non-responsive to sildenafil. The mechanism of action is complementary to PDE5 inhibitors, which is why some practitioners prescribe both together for treatment-resistant ED.⁶

The male evidence is thinner than the female evidence. It comes from small phase 2 studies, and no phase 3 trial in men led to an approval. Men exploring it usually do so with a urologist or men’s health physician after a standard workup for erectile dysfunction, which checks heart health, diabetes and testosterone. Our overview of ED treatment options covers the first-line choices, and the piece on peptides for erectile dysfunction compares PT-141 with other peptides marketed for ED.

Male Low Desire

Low testosterone is the most common hormonal cause of low libido in men, and testosterone replacement therapy (TRT) is the first-line treatment. But some men on adequate TRT still experience suboptimal desire. PT-141 can serve as an adjunct in these cases, addressing the central arousal pathway that testosterone alone may not fully activate.

Administration: How PT-141 Is Used

Subcutaneous Injection

The FDA-approved route for Vyleesi is subcutaneous injection. The standard dose is 1.75 mg injected into the abdomen or thigh at least 45 minutes before anticipated sexual activity. The autoinjector makes self-administration straightforward.

MedlinePlus, the National Library of Medicine’s drug reference, adds practical detail: inject into the stomach area or the front of the thigh, stay at least 2 inches from the belly button, rotate sites, and use a new autoinjector each time.

Nasal Spray

Compounding pharmacies also prepare PT-141 as a nasal spray, which many patients prefer for convenience. Typical nasal spray doses range from 400 to 600 mcg per spray, with 1 to 2 sprays (total dose 400 to 1200 mcg) used 30 to 60 minutes before activity. Absorption through nasal mucosa is rapid, and some users report faster onset compared to subcutaneous injection.

The nasal form is not FDA approved. Early development of intranasal PT-141 was set aside in favor of the injection, partly because of blood pressure effects, and compounded sprays and vials have not gone through FDA review for consistency. Ask the prescriber which pharmacy prepares the product and how it is tested.

Side Effects and Safety

The side effect profile of PT-141 is well characterized from clinical trials and post-market use. In the phase 3 trials, the FDA prescribing information reports nausea in 40.0% of women on bremelanotide versus 1.3% on placebo, flushing in 20.3%, injection site reactions in 13.2%, headache in 11.3% and vomiting in 4.8%.

Common Side Effects

• Nausea: The most significant side effect, affecting approximately 40% of users in clinical trials. Usually mild to moderate, peaks about 2 hours after injection, and typically improves with repeated use. Taking an anti-nausea medication (ondansetron/Zofran) 30 minutes before PT-141 can help manage this.
• Flushing: Temporary facial and body flushing, similar to niacin flush. Occurs in about 20% of users.
• Headache: Reported in approximately 10 to 15% of users.
• Injection site reactions: Mild redness or irritation at the injection site. More common with repeated injections in the same area.

Cardiovascular Considerations

The FDA label gives the exact figures: bremelanotide raised systolic blood pressure by up to 6 mmHg and diastolic by up to 3 mmHg, peaking 2 to 4 hours after the dose, with heart rate falling by up to 5 beats per minute. Both usually returned to baseline within 12 hours. The label contraindicates it in uncontrolled hypertension and known cardiovascular disease.

Other Safety Notes

• Skin darkening: Because PT-141 retains some melanocortin-1 receptor activity (the tanning receptor), some users notice darkening of the skin, including existing moles or freckles. The FDA label reports focal hyperpigmentation of the face, gums or breasts in 1% of trial patients, and resolution after stopping was not confirmed in all of them. MedlinePlus notes the risk is higher in people with darker skin and with use on 8 days in a row, so changes should be monitored.
• Tolerance: Some users report diminished response with frequent use, which is one reason for the recommended frequency limits. Periodic breaks may help maintain efficacy.
• Drug interactions: Bremelanotide slows stomach emptying and can lower the absorption of some oral drugs. The label says to avoid it with oral naltrexone products used for alcohol or opioid dependence, and MedlinePlus also flags indomethacin and oral antibiotics. People on low-dose naltrexone should raise it with the prescriber, since it is the same oral drug. PT-141 should not be combined with other melanocortin receptor agonists, and caution applies with medications that affect blood pressure.
• Pregnancy: MedlinePlus advises effective birth control during treatment and a call to the doctor if pregnancy occurs.

Cost and Access

Vyleesi (brand-name bremelanotide) carries a list price of approximately $850 to $1,000 per month (for 8 autoinjector doses). Insurance coverage varies significantly; some plans cover it for HSDD with prior authorization, while many do not.

Compounded PT-141 (available through compounding pharmacies with a prescription) is considerably less expensive, typically $100 to $300 per month depending on the form (injectable vial vs. nasal spray) and the pharmacy. Many functional and integrative medicine practitioners prescribe compounded PT-141, particularly for male patients (since Vyleesi is approved only for women).

Off-label and compounded use is almost always cash pay. Before starting, ask whether the quoted price includes the consultation, blood pressure checks and follow-up visits, and whether the pharmacy is a licensed compounding pharmacy.

Who Is PT-141 Best Suited For?

PT-141 is not a universal solution for sexual dysfunction. It works best for specific clinical profiles:

• Women with HSDD: The FDA-approved indication. Best candidates are premenopausal women with persistently low desire that causes distress, not explained by other medical conditions, medications, or relationship factors.
• Men with desire-related ED: Men whose erectile dysfunction has a significant psychological or low-desire component, particularly those who have not fully responded to PDE5 inhibitors alone.
• Combined with PDE5 inhibitors: For men with treatment-resistant ED, PT-141 plus a PDE5 inhibitor addresses both the central (desire/arousal) and peripheral (blood flow) components simultaneously.
• SSRI-related sexual dysfunction: Antidepressants commonly suppress sexual desire. PT-141 may partially counteract this by stimulating arousal through a separate pathway, though controlled evidence for this use is limited.

PT-141 is less likely to help when sexual dysfunction is purely mechanical (severe vascular ED without a desire component) or driven by relationship conflict, severe hormonal deficiency (where hormone replacement should come first), or untreated depression.

Does PT-141 Improve Longevity or Overall Wellness?

PT-141 improves sexual health through one route: it raises desire and arousal by activating melanocortin receptors in the brain. No clinical trial has tested bremelanotide for lifespan, aging markers, energy or general wellness, and it has no approved use outside HSDD.

The link to wellness is indirect. Low desire that causes distress weighs on mood, relationships and quality of life, and for women who respond, easing that distress was a measured outcome in the RECONNECT trials. That is a sexual health benefit, not an anti-aging effect.

Some longevity and wellness clinics include PT-141 in broader peptide protocols. When it appears in a longevity package, ask what condition it is treating, how blood pressure will be checked, and what the plan is if desire does not improve within 8 weeks. Our explainer on whether peptides are safe covers the wider regulatory picture.

Who Prescribes PT-141 and How to Find a Clinic

Vyleesi is prescribed by OB-GYNs, women’s health and menopause clinicians, sexual medicine specialists and primary care physicians. Compounded PT-141 is more often prescribed in peptide therapy, men’s health, urology and integrative medicine practices. A careful prescriber screens for heart disease, blood pressure, medications and hormone levels before the first dose, and looks for relationship or mood factors that a drug cannot address.

The Regenerated.com directory of peptide therapy clinics across the US lists practices that report offering peptides such as PT-141, and the peptide therapy treatment guide explains how these protocols are usually structured. Men comparing desire and erection treatments can also browse clinics that treat erectile dysfunction.

The directory is free for patients. Listing order is not paid ranking, Featured slots are labeled and capped, and Verified means a clinic has passed credential checks, not that it paid more. Inclusion in the directory is not an endorsement, and the guide to Featured, Verified and organic listings explains each label.

Frequently Asked Questions About PT-141

What is bremelanotide used for?

Bremelanotide is used to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, the only use the FDA approved in 2019 under the brand name Vyleesi. It is a 1.75 mg injection taken at least 45 minutes before sex. Clinicians also prescribe compounded bremelanotide, called PT-141, off label for men with low desire or erectile dysfunction that has not responded to PDE5 inhibitors, though that use rests on smaller studies.

How does PT-141 improve sexual health?

PT-141 improves sexual health by activating melanocortin-4 receptors in the hypothalamus and limbic system, brain areas that drive sexual desire and arousal. Blood-flow drugs such as Viagra and Cialis act on the genitals instead. In the RECONNECT trials, about 25% of women on bremelanotide reported a meaningful rise in desire versus 17% on placebo. It has not been studied as a longevity or general wellness treatment, so its benefit is limited to desire and arousal.

Does PT-141 work for men?

PT-141 has shown effects in men in phase 2 studies, including some men whose erectile dysfunction did not respond to sildenafil, but it is not FDA approved for men. Vyleesi’s label states it is not indicated for men. Men who use it get a compounded product prescribed off label, usually by a urologist, men’s health or peptide therapy clinician, and should have heart health and blood pressure checked first because the drug briefly raises blood pressure.

How long does PT-141 take to work, and how long does it last?

PT-141 reaches its peak blood level about 1 hour after a subcutaneous injection, which is why the label calls for dosing at least 45 minutes before sexual activity. Its half-life is about 2.7 hours, according to the FDA prescribing information, while users often describe effects on desire lasting 6 to 12 hours. Blood pressure changes usually settle within 12 hours. Women should stop after 8 weeks if desire has not improved.

Is PT-141 the same as Melanotan II?

PT-141 is not the same as Melanotan II, although it was developed from it. Melanotan II is an older tanning peptide that activates several melanocortin receptors, and it was never approved by the FDA. Bremelanotide is a modified form that keeps the sexual arousal effect with less tanning activity, and it went through phase 3 trials and FDA approval as Vyleesi. Products sold online as Melanotan II are unregulated and are not a substitute for a prescription.

Can you take PT-141 with Viagra or Cialis?

Some clinicians prescribe PT-141 together with a PDE5 inhibitor such as Viagra (sildenafil) or Cialis (tadalafil) for men with treatment-resistant erectile dysfunction, because the two act on different pathways: desire in the brain and blood flow in the penis. The combination is off label and has limited trial data. Because both drugs affect blood pressure, it should only be used under a prescriber who has checked cardiovascular health and current medications.

Related Reading

• Peptide Therapy: The Complete Guide
• Erectile Dysfunction: The Evidence-Based Guide
• ED Treatment Comparison: Medications, Devices, and Regenerative Options
• Low Libido in Women: Causes, Testing, and Treatment Options
• Peptides for Erectile Dysfunction

Sources

1. Wessells H, Fuciarelli K, Hansen J, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol. 1998;160(2):389-393. doi:10.1016/S0022-5347(01)62904-0 ↩
2. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930. doi:10.1016/j.peptides.2005.01.029 ↩
3. Goldstein I, Kim NN, Clayton AH, et al. Hypoactive sexual desire disorder: International Society for the Study of Women’s Sexual Health (ISSWSH) expert consensus panel review. Mayo Clin Proc. 2017;92(1):114-128. doi:10.1016/j.mayocp.2016.09.018 ↩
4. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899-908. doi:10.1097/AOG.0000000000003500 ↩
5. Clayton AH, Althof SE, Kingsberg S, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond). 2016;12(3):325-337. doi:10.2217/whe-2016-0018 ↩
6. Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2006;18(1):58-63. doi:10.1038/sj.ijir.3901371 ↩
7. US Food and Drug Administration. VYLEESI (bremelanotide injection), for subcutaneous use: prescribing information. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
8. MedlinePlus, US National Library of Medicine. Bremelanotide injection. https://medlineplus.gov/druginfo/meds/a619054.html